Menu Search
Equities

TYK Medicines Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2410:HKG.HS

TYK Medicines Inc

Actions
  • Price (HKD)12.80
  • Today's Change0.13 / 1.03%
  • Shares traded1.13m
  • 1 Year change-45.65%
  • Beta--
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

TYK Medicines Inc is a China-based company mainly engaged in developing and commercializing pharmaceutical products. The Company is primarily focused on small molecule drug development, and its main products include TY-9591, TY-302 and TY-2136. TY-9591 is a third-generation EGFR-TKI with antitumor effects on EGFR mutations. TY-302 is a potent, selective oral CDK4/6 inhibitor developed for the treatment of advanced solid tumors, including breast cancer and prostate cancer. TY-2136b is an internally developed, oral ROS1/NTRK inhibitor for the treatment of solid tumors.

  • Revenue in HKD (TTM)121.19k
  • Net income in HKD-317.21m
  • Incorporated2017
  • Employees163.00
  • Location
    TYK Medicines Inc500 Yunjin Road, Greenland VilSHANGHAI 200030ChinaCHN
  • Phone+86 2 161676766
  • Fax+86 2 160107317
  • Websitehttps://www.tykmedicines.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.